Tetrahydropyrrolocyclic OX-2 Antagonists for Brain-Penetrant Insomnia Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases related to orexin signaling pathways, such as insomnia and depression, lack effective and selective orexin-2 receptor antagonists that can cross the blood-brain barrier and provide therapeutic benefits.
Innovation Solution
Development of tetrahydropyrrolocyclic compounds with specific substituents that act as selective orexin-2 receptor antagonists, exhibiting good pharmacokinetic properties and ability to penetrate the blood-brain barrier.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for diseases related to orexin signaling pathways are used, then therapeutic effects are limited, but the lack of effective and selective orexin-2 receptor antagonists that can cross the blood-brain barrier is the main problem
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of tetrahydropyrrolocyclic compounds, including varying substituents R1-R6, ring sizes m and n, and ring A and B structures to optimize both the selective antagonism of OX-2 receptors and the ability to cross the blood-brain barrier. This structure-activity relationship optimization enables the compounds to achieve both therapeutic effectiveness and blood-brain barrier penetration.
Solution Approach 2:
The patent applies local quality by introducing specific functional groups and substituents at particular positions on the tetrahydropyrrolocyclic core structure. Different substituents (halogen, cyano, alkyl, alkoxy groups) are placed at specific positions (R1-R6) to locally enhance either receptor selectivity or blood-brain barrier permeability, allowing the molecule to fulfill multiple functions simultaneously.
2Adaptability or versatility
If selective orexin-2 receptor antagonists are developed, then therapeutic potential for insomnia and depression is improved, but the complexity of achieving both selectivity and blood-brain barrier penetration increases
Solution Approach 1:
The patent applies segmentation by dividing the molecular design into distinct functional modules: the tetrahydropyrrolocyclic core structure provides the basic scaffold for OX-2 receptor binding, while separate substituent groups (R1-R6) and ring systems (A and B) are independently optimized to provide blood-brain barrier penetration and selective antagonism, respectively. This modular approach simplifies the overall design complexity.
Solution Approach 2:
The patent applies universality by designing a multi-functional tetrahydropyrrolocyclic compound that simultaneously provides: (1) selective OX-2 receptor antagonism through specific molecular recognition, (2) blood-brain barrier penetration through optimized lipophilicity and molecular size, and (3) pharmacokinetic stability. This single molecule performs multiple essential functions that would otherwise require separate compounds.
Data Source
AI summary
A tetrahydropyrrolocyclic compound as represented by formula (I), a pharmaceutically acceptable salt thereof, and an application thereof in preparation of a drug for treating a disease related to a selective orexin-2 (OX-2) receptor antagonist, wherein the related disease is selected from insomnia and depression.